This document discusses the management of gastrointestinal bleeding. It covers the clinical presentation and definitions of acute upper and lower GI bleeding. The core principles of GI bleeding management are outlined as assessing and stabilizing hemodynamic status, determining the source of bleeding, stopping active bleeding, treating any underlying abnormalities, and preventing recurrent bleeding. Specific causes, diagnostic evaluations, endoscopic and surgical treatments are described for various types of acute GI bleeding.

1. Gastrointestinal Bleeding
Abdur Rahman
Group-115

2. GI Bleeding
 Clinical Presentation
 Acute Upper GI Bleed
 Acute Lower GI Bleed

3. Core Principles in
GI Bleeding Management
 Assessment and stabilization of hemodynamic status
 Determine the source of bleeding
 Stop active bleeding
 Treatment of underlying abnormality
 Prevent recurrent bleeding

4. GI Bleeding Management
Definitions
Hematemesis: bloody vomitus (bright red or
coffee-grounds)
Melena: black, tarry, foul-smelling stool
Hematochezia: bright red or maroon blood
per rectum
Occult: positive stool occult test
Symptoms of anemia: angina, dyspnea, or
lightheadedness

5. GI Bleeding Management
Patient Assessment
 Hemodynamic status
 Localization of bleeding source
 CBC, PT, and T & C
 Risk factors
 Prior h/o PUD or bleeding
 Cirrhosis
 Coagulopathy
 ASA or NSAID’s

6. GI Bleeding Management
Initial Patient Assessment
Vital Signs Blood Loss
Severity of GI
Bleed
Shock
(resting hypotension)
20-25% Massive
Postural
(orthostatic hypotension)
10-20% Moderate
Normal <10% Minor

7. GI Bleeding Management
Resuscitation
 2 large bore peripheral IV’s
 Normal saline or LR
 Packed RBCs
 Correct coagulopathy

8. GI Bleeding Management
Location of Bleeding
 Upper
 Proximal to Ligament of Treitz
 Melena (100-200 cc of blood)
 Azotemia
 Nasogastric aspirate
 Lower
 Distal to Ligament of Treitz
 Hematochezia

9. Acute UGIB
Demographics
Over 400,000 admissions annually
80% self-limited
Mortality 10-14%
Continued or recurrent bleeding - mortality 30-
40%
Nonvariceal UGIB w/o complication*
 Mean LOS 2.7 days, $3402 (2008 $)
Nonvariceal UGIB with complication*
 Mean LOS 4.4 days, $5632 (2008 $)
Adam V, Barkun A. Value Health. 2008;11:1-3.

10. Risk
Stratification
Scoring
Systems

11. Blatchford Score
Rockall Score

12. UGIB Risk Stratification – AIMS65
 Albumin < 3.0 g/dL,
 INR > 1.5,
 Altered mental status,
 Systolic blood
pressure 90 mm Hg
or lower, and
 Age older > 65 years.
Saltzman JR et al. Gastrointest Endosc 2011:1215-22.
• Large clinical
database -
CareFusion
• 187 US hospitals
• Recursive partitioning
• 2004-5 29,222 pts to
derive risk score
• 2006-7 32,504 pts to
validate

13. UGIB Risk Stratification – AIMS65
Saltzman JR et al. Gastrointest Endosc 2011:1215-22.

14. Acute UGIB
Differential Diagnosis
 Peptic ulcer disease
 Gastric ulcer
 Duodenal ulcer
 Mallory-Weiss tear
 Varices
 Esophagitis
 Dieulafoy’s lesion
 Vascular anomalies
 Malignancy
 Post-procedural
 Cameron’s lesions
 Hemobilia
 Hemorrhagic
gastropathy
 Aortoenteric fistula
Major Causes Minor Causes

15. Peptic Ulcer Disease
Forrest Class Stigmata
IA Arterial spurting
IB Arterial oozing
IIA Visible vessel
IIB Adherent clot
IIC Pigmented flat spot
III Clean based
Forrest JA, Finlayson ND, Shearman DJ: Endoscopy in gastrointestinal bleeding. Lancet 1974; 2:394-7

16. Endoscopic Appearance
of Ulcers
Clean based ulcer Nonbleeding visible vessel

17. Risk Stratification after
Endoscopy

18. Endoscopic Therapy of PUD
 Thermal
 Bipolar probe
 Monopolar probe
 Argon plasma
coagulator
 Heater probe
 Mechanical
 Hemoclips
 Band ligation
 Injection
 Epinephrine
 Alcohol
 Ethanolamine
 Polidocal

19. Endoscopic Therapy of PUD
Laine and Peterson New Eng J Med 1994;331:717-27.

20. Risk of Recurrent Bleeding
after Endoscopic Therapy

21. Effect of Proton-Pump Inhibition on Peptic Ulcer
Bleeding
Gralnek et al. New Eng J Med 2008;359:928-37.

22. Management of PUD
after EGD in High Risk Pts
 Proton-pump inhibitor 80 mg IV bolus dose plus continuous infusion for
72 hrs
 Admit to monitored bed or ICU setting
 Initiate oral intake of clear liquid diet 6 hrs after EGD in pts with
hemodynamic stability
 Transition to oral PPI after completing IV course
 Perform testing for H. pylori infection
 For selected patients, discuss need for NSAIDs and antiplatelet therapy
Gralnek et al. New Eng J Med 2008;359:928-37.

23. Management of PUD
after EGD in Low Risk Pts
 Oral proton-pump inhibitor
 Initiate oral intake with a regular diet 6 hrs after EGD in pts with hemodynamic
stability
 Perform testing for H. pylori infection
 For selected patients, discuss need for NSAIDs and antiplatelet therapy
 Consider early discharge in selected pts
Gralnek et al. New Eng J Med 2008;359:928-37.

24. Mallory-Weiss Tear

25. Esophageal Varices

26. Management of
Acute Variceal Bleeding
Suspected Variceal Bleeding
Endoscopy
Band ligation or sclerotherapy
Continue Octreotide for 5 days
Early rebleeding
Failure to control TIPS or surgery
Octreotide 50 ug bolus, 50 ug/hr
Conservative blood volume resuscitation
Antibiotics

27. Antibiotic Prophylaxis in GI
Bleeding in Cirrhotic Patients
 Fluoroquinolones or amoxicillin + clavulinic acid
 Meta-analysis 1
 Decrease rates of infection
 SBP, bacteremia
 Increased short-term survival
 RCT 2
 Reduction in early rebleeding
1.Bernard et al.Hepatology. 29(6):1655-61.1999.
2.Hou et al. Hepatology. 39(3):746-53.2004.

28. Variceal Band Ligation

29. Transjugular Intrahepatic Portosystemic Shunt
(TIPS)
IVC
Portal Vein
Splenic Vein
Coronary Vein

30. Aortoduodenal Fistula
Aorta
Duodenum
Graft
Fistula

31. Acute UGIB
Surgery
 Recurrent bleeding despite endoscopic therapy
 > 6-8 units pRBCs

32. Management of Ulcer Bleeding: ACG Guidelines
Initial Assessment and Risk Stratification
 Hemodynamic status should be assessed immediately upon presentation
and resuscitative measures begun as needed (Strong recommendation).
 Blood transfusions should target Hgb ≥ 7 g / dl, with higher Hgbs targeted in
patients with clinical evidence of intravascular volume depletion or
comorbidities, such as coronary artery disease (Conditional
recommendation).
 Risk assessment should be performed to stratify patients into higher and
lower risk categories and may assist in initial decisions such as timing of
endoscopy, time of discharge, and level of care (Conditional
recommendation).
 Discharge from the ED without inpatient endoscopy may be considered in
patients with urea nitrogen < 18.2 mg / dl; Hgb ≥ 13.0 g / dl for men (12.0 g /
dl for women), systolic blood pressure ≥ 110 mm Hg; pulse < 100 beats /
min; and absence of melena, syncope, cardiac failure, and liver disease, as
they have < 1 % chance of requiring intervention (Conditional
recommendation).
Laine & Jensen Am J Gastroenterol 2012; 107:345–360

33. Management of Ulcer Bleeding: ACG Guidelines
Pre-endoscopic interventions
 Intravenous infusion of erythromycin (250 mg ~ 30 min before
endoscopy) should be considered to improve diagnostic yield and
decrease the need for repeat endoscopy. However, erythromycin
has not consistently been shown to improve clinical outcomes
(Conditional recommendation).
 Pre-endoscopic intravenous PPI (e.g., 80 mg bolus followed by 8 mg
/ h infusion) may be considered to decrease the proportion of
patients who have higher risk stigmata of hemorrhage at endoscopy
and who receive endoscopic therapy. However, PPIs do not improve
clinical outcomes such as further bleeding, surgery, or death
(Conditional recommendation).
 If endoscopy will be delayed or cannot be performed, intravenous
PPI is recommended to reduce further bleeding (Conditional
recommendation).
 Nasogastric or orogastric lavage is not required in patients with
UGIB for diagnosis, prognosis, visualization, or therapeutic effect
(Conditional recommendation).
Laine & Jensen Am J Gastroenterol 2012; 107:345–360

34. Management of Ulcer Bleeding: ACG Guidelines
Timing of endoscopy
 Patients with UGIB should generally undergo endoscopy
within 24 h of admission, following resuscitative efforts to
optimize hemodynamic parameters and other medical
problems (Conditional recommendation).
 In patients who are hemodynamically stable and without
serious comorbidities endoscopy should be performed as
soon as possible in a non-emergent setting to identify the
substantial proportion of patients with low-risk endoscopic
findings who can be safely discharged (Conditional
recommendation).
 In patients with higher risk clinical features (e.g., tachycardia,
hypotension, bloody emesis or nasogastric aspirate in
hospital) endoscopy within 12 h may be considered to
potentially improve clinical outcomes (Conditional
recommendation).
Laine & Jensen Am J Gastroenterol 2012; 107:345–360

35. Management of Ulcer Bleeding: ACG Guidelines -
Endoscopy
 Stigmata of recent hemorrhage should be recorded as they predict risk of
further bleeding and guide management decisions. The stigmata, in
descending risk of further bleeding, are active spurting, non-bleeding visible
vessel, active oozing, adherent clot, fl at pigmented spot, and clean base
(Strong recommendation).
 Endoscopic therapy should be provided to patients with active spurting or
oozing bleeding or a non-bleeding visible vessel (Strong recommendation).
 Endoscopic therapy may be considered for patients with an adherent clot
resistant to vigorous irrigation. Benefi t may be greater in patients with
clinical features potentially associated with a higher risk of rebleeding (e.g.,
older age, concurrent illness, inpatient at time bleeding began) (Conditional
recommendation).
 Endoscopic therapy should not be provided to patients who have an ulcer
with a clean base or a fl at pigmented spot (Strong recommendation).
Laine & Jensen Am J Gastroenterol 2012; 107:345–360

36. Management of Ulcer Bleeding: ACG Guidelines - Endoscopy
 Epinephrine therapy should not be used alone. If used, it should be
combined with a second modality (Strong recommendation).
 Thermal therapy with bipolar electrocoagulation or heater probe and
injection of sclerosant (e.g., absolute alcohol) are recommended
because they reduce further bleeding, need for surgery, and mortality
(Strong recommendation).
 Clips are recommended because they appear to decrease further
bleeding and need for surgery. However, comparisons of clips vs. other
therapies yield variable results and currently used clips have not been
well studied (Conditional recommendation).
 For the subset of patients with actively bleeding ulcers, thermal therapy
or epinephrine plus a second modality may be preferred over clips or
sclerosant alone to achieve initial hemostasis (Conditional
recommendation).
Laine & Jensen Am J Gastroenterol 2012; 107:345–360

37. Management of Ulcer Bleeding: ACG Guidelines - Therapy
after initial endoscopy
 After successful endoscopic hemostasis, intravenous PPI therapy with 80 mg
bolus followed by 8 mg/h continuous infusion for 72 h should be given to
patients who have an ulcer with active bleeding, a non-bleeding visible vessel,
or an adherent clot (Strong recommendation).
 Patients with ulcers that have flat pigmented spots or clean bases can receive
standard PPI therapy (e.g., oral PPI once daily) (Strong recommendation).
 Routine second-look endoscopy, in which repeat endoscopy is performed 24 h
after initial endoscopic hemostatic therapy, is not recommended (Conditional
recommendation).
 Repeat endoscopy should be performed in patients with clinical evidence of
recurrent bleeding and hemostatic therapy should be applied in those with
higher risk stigmata of hemorrhage (Strong recommendation).
 If further bleeding occurs after a second endoscopic therapeutic session,
surgery or interventional radiology with transcathether arterial embolization is
generally employed (Conditional recommendation).
Laine & Jensen Am J Gastroenterol 2012; 107:345–360

38. International Consensus on Nonvariceal Upper
Gastrointestinal Bleeding:
Postdischarge ASA and NSAIDs
 In patients with previous ulcer bleeding who require
an NSAID, it should be recognized that treatment
with a traditional NSAID plus PPI or a COX-2 inhibitor
alone is still associated with a clinically important risk
for recurrent ulcer bleeding.
 In patients with previous ulcer bleeding who require
an NSAID, the combination of a PPI and a COX-2
inhibitor is recommended to reduce the risk for
recurrent bleeding from that of COX-2 inhibitors
alone.
Barkun AN, et al. Ann Intern Med. 2010;152:101-113.

39. International Consensus on Nonvariceal Upper
Gastrointestinal Bleeding:
Postdischarge ASA and NSAIDs
 In patients who receive low-dose ASA and develop
acute ulcer bleeding, ASA therapy should be
restarted as soon as the risk for cardiovascular
complication is thought to outweigh the risk for
bleeding.
 In patients with previous ulcer bleeding who require
cardiovascular prophylaxis, it should be recognized
that clopidogrel alone has a higher risk for rebleeding
than ASA combined with a PPI.
Barkun AN, et al. Ann Intern Med. 2010;152:101-113.

40. Acute LGIB
Differential Diagnosis
 Diverticulosis
 Colitis
 IBD (UC>>CD)
 Ischemia
 Infection
 Vascular anomalies
 Neoplasia
 Anorectal
 Hemorrhoids
 Fissure
 Dieulafoy’s lesion
 Varices
 Small bowel
 Rectal
 Aortoenteric fistula
 Kaposi’s sarcoma
 UPPER GI BLEED

41. Diverticulosis

42. Diverticular Bleeding

43. Hemorrhoids

44. Bleeding AVM

45. Radiation Proctitis

46. Acute LGIB
Meckel’s Diverticulum
 Incidence 0.3 - 3.0 %
 Etiology Incomplete obliteration of
the vitelline duct.
 Pathology 50% ileal, 50% gastric,
pancreatic, colonic mucosa
 Complications
 Painless bleeding (children, currant jelly)
 Intussusception

47. Acute LGIB
Key Points
 Resuscitation
 UGI source
 Most bleeding ceases
 Colonoscopy
 No role for barium studies

48. SUMMARY
GI Bleeding Management
 Assessment and stabilization of hemodynamic status
 Determine the source of bleeding
 Stop active bleeding
 Treatment of underlying abnormality
 Prevent recurrent bleeding